ATYR Stock Catalyst: aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

Sep 24, 2026 · 6:06am ET

Company expects to initiate study-related activities in Q4 2026.

Max move

+90.1%

High of day $0.73

Sparker timei

6:06am ET

ATYR · Sep 24, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

aTyr Pharma Inc (Nasdaq: ATYR) announced alignment with the FDA on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, targeting patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company anticipates initiating study-related activities in the fourth quarter of 2026.

The Phase 3 study will evaluate the efficacy and safety of efzofitimod in the specified patient population. aTyr Pharma's free float stands at 95,515,301 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ATYR sparks.

Download Sniper App →

Catch the next ATYR-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →